• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.

作者信息

Lim Jeong Uk, Kang Hye Seon

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

出版信息

Transl Lung Cancer Res. 2021 Sep;10(9):3709-3712. doi: 10.21037/tlcr-21-764.

DOI:10.21037/tlcr-21-764
PMID:34733622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8512462/
Abstract
摘要

相似文献

1
Expert consensus on perioperative immunotherapy for locally advanced non-small cell lung cancer.局部晚期非小细胞肺癌围手术期免疫治疗专家共识
Transl Lung Cancer Res. 2021 Sep;10(9):3709-3712. doi: 10.21037/tlcr-21-764.
2
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).癌症免疫治疗学会关于免疫治疗非小细胞肺癌（NSCLC）的共识声明。
J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.
3
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer.局部晚期非小细胞肺癌围手术期免疫治疗专家共识
Transl Lung Cancer Res. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634.
4
[Chinese expert consensus on perioperative treatment of locally advanced gastric cancer (2021 version)].《中国局部进展期胃癌围手术期治疗专家共识（2021年版）》
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):741-748. doi: 10.3760/cma.j.cn.441530-20210831-00351.
5
Immunotherapy for Lung Cancer-Improving Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer With Immunotherapy.肺癌的免疫治疗——免疫治疗改善局部晚期非小细胞肺癌患者的结局。
Cancer J. 2020 Nov/Dec;26(6):548-554. doi: 10.1097/PPO.0000000000000485.
6
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.免疫治疗之外的治疗选择：野生型肺腺癌患者的德尔菲共识。
Clin Transl Oncol. 2020 May;22(5):759-771. doi: 10.1007/s12094-019-02191-y. Epub 2019 Jul 31.
7
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer.非小细胞肺癌的围手术期靶向治疗或免疫治疗
Onco Targets Ther. 2019 Oct 3;12:8151-8159. doi: 10.2147/OTT.S222412. eCollection 2019.
8
Emerging role of immunotherapy in locally advanced non-small cell lung cancer.免疫疗法在局部晚期非小细胞肺癌中的新作用。
Clin Adv Hematol Oncol. 2020 Apr;18(4):212-217.
9
Locally Advanced, Unresectable Non-Small Cell Lung Cancer.局部晚期、不可切除的非小细胞肺癌。
Curr Oncol Rep. 2020 Mar 5;22(4):31. doi: 10.1007/s11912-020-0882-3.
10
Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.非小细胞肺癌围手术期免疫治疗专家共识：一篇社论
Transl Lung Cancer Res. 2021 Dec;10(12):4322-4327. doi: 10.21037/tlcr-21-882.

引用本文的文献

1
Impact of preoperative chemotherapy on cutaneous wound healing in lung cancer patients: A meta-analysis.术前化疗对肺癌患者皮肤切口愈合的影响：一项荟萃分析。
Int Wound J. 2024 Apr;21(4):e14518. doi: 10.1111/iwj.14518. Epub 2023 Dec 20.

本文引用的文献

1
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.循环肿瘤 DNA 作为生物标志物，用于监测接受免疫检查点抑制剂治疗的晚期肺腺癌患者的早期治疗反应。
Mol Oncol. 2021 Nov;15(11):2910-2922. doi: 10.1002/1878-0261.13090. Epub 2021 Sep 25.
2
Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.可切除非小细胞肺癌患者的新辅助化疗免疫治疗。
Curr Treat Options Oncol. 2021 Aug 23;22(10):91. doi: 10.1007/s11864-021-00885-6.
3
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA.奥希替尼新辅助治疗联合/不联合化疗对比单纯化疗用于可切除 - 突变型非小细胞肺癌：NeoADAURA 研究。
Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.
4
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.SAKK 16/14：在 IIIA（N2）期非小细胞肺癌患者中，新辅助化疗联合度伐利尤单抗：一项多中心单臂 II 期试验。
J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12.
5
Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.新辅助表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌患者疗效与安全性的当前证据
Front Oncol. 2021 May 24;11:608608. doi: 10.3389/fonc.2021.608608. eCollection 2021.
6
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).免疫疗法与辅助治疗切除的非小细胞肺癌的整合：ALCHEMIST 化疗免疫联合（ACCIO）。
Immunotherapy. 2021 Jun;13(9):727-734. doi: 10.2217/imt-2021-0019. Epub 2021 Apr 21.
7
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.非小细胞肺癌患者围手术期免疫治疗相关不良事件的临床推荐。
Thorac Cancer. 2021 May;12(9):1469-1488. doi: 10.1111/1759-7714.13942. Epub 2021 Mar 30.
8
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.可切除非小细胞肺癌的新辅助纳武利尤单抗或纳武利尤单抗联合伊匹单抗：Ⅱ期随机 NEOSTAR 试验。
Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18.
9
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.可切除非小细胞肺癌患者新辅助阿替利珠单抗和化疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):786-795. doi: 10.1016/S1470-2045(20)30140-6. Epub 2020 May 7.
10
The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.F-FDG PET-CT预测可切除非小细胞肺癌新辅助PD-1阻断治疗主要病理反应的效能
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1209-1219. doi: 10.1007/s00259-020-04711-3. Epub 2020 Feb 11.